keyword
MENU ▼
Read by QxMD icon Read
search

Ocular oncology

keyword
https://www.readbyqxmd.com/read/28822576/pembrolizumab-versus-ipilimumab-for-advanced-melanoma-final-overall-survival-results-of-a-multicentre-randomised-open-label-phase-3-study-keynote-006
#1
Jacob Schachter, Antoni Ribas, Georgina V Long, Ana Arance, Jean-Jacques Grob, Laurent Mortier, Adil Daud, Matteo S Carlino, Catriona McNeil, Michal Lotem, James Larkin, Paul Lorigan, Bart Neyns, Christian Blank, Teresa M Petrella, Omid Hamid, Honghong Zhou, Scot Ebbinghaus, Nageatte Ibrahim, Caroline Robert
BACKGROUND: Interim analyses of the phase 3 KEYNOTE-006 study showed superior overall and progression-free survival of pembrolizumab versus ipilimumab in patients with advanced melanoma. We present the final protocol-specified survival analysis. METHODS: In this multicentre, open-label, randomised, phase 3 trial, we recruited patients from 87 academic institutions, hospitals, and cancer centres in 16 countries (Australia, Austria, Belgium, Canada, Chile, Colombia, France, Germany, Israel, Netherlands, New Zealand, Norway, Spain, Sweden, UK, and USA)...
August 16, 2017: Lancet
https://www.readbyqxmd.com/read/28730794/athens-eye-hospital-ocular-oncology-multidisciplinary-team-providing-combined-treatments-for-patients-with-choroidal-melanoma-3-years-results
#2
Anastasios Anastasakis, Panagiotis Zafeirakis, Charalampos Livir-Rallatos, Gerasimos Livir-Rallatos
No abstract text is available yet for this article.
May 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28730793/athens-eye-hospital-ocular-oncology-multidisciplinary-team-providing-combined-treatments-for-patients-with-choroidal-melanoma-3-years-results
#3
Anastasios Anastasakis, Panagiotis Zafeirakis, Charalampos Livir-Rallatos, Gerasimos Livir-Rallatos, Mutlu Hayran
No abstract text is available yet for this article.
May 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28688625/bilateral-retrobulbar-optic-neuropathy-as-the-only-sign-of-zoledronic-acid-toxicity
#4
Félix Manco Lavado, Marta Para Prieto, María Rosalba Ramoa Osorio, María Isabel López Gálvez, Lucía Manzanas Leal
INTRODUCTION: Bisphosphonates may rarely cause ocular adverse effects and retrobulbar optic neuropathy (RON) secondary to zoledronic acid is very rare. CASE REPORT: A 67-year-old man was referred because of progressive and painless decrease vision in the left eye. He had been treated with 7 cycles of zoledronic acid infusions because of metastatic prostate cancer. On examination, VA was 20/20 in the right eye (OD) and 20/50 in the left eye (OS). The optic nerve was unremarkable OU...
July 5, 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/28674118/retinoblastoma-and-neuroblastoma-predisposition-and-surveillance
#5
REVIEW
Junne Kamihara, Franck Bourdeaut, William D Foulkes, Jan J Molenaar, Yaël P Mossé, Akira Nakagawara, Andreu Parareda, Sarah R Scollon, Kami Wolfe Schneider, Alison H Skalet, Lisa J States, Michael F Walsh, Lisa R Diller, Garrett M Brodeur
Retinoblastoma (RB) is the most common intraocular malignancy in childhood. Approximately 40% of retinoblastomas are hereditary and due to germline mutations in the RB1 gene. Children with hereditary RB are also at risk for developing a midline intracranial tumor, most commonly pineoblastoma. We recommend intensive ocular screening for patients with germline RB1 mutations for retinoblastoma as well as neuroimaging for pineoblastoma surveillance. There is an approximately 20% risk of developing second primary cancers among individuals with hereditary RB, higher among those who received radiotherapy for their primary RB tumors...
July 1, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28648699/prognostic-factors-and-outcomes-in-metastatic-uveal-melanoma-treated-with-programmed-cell-death-1-or-combined-pd-1-cytotoxic-t-lymphocyte-antigen-4-inhibition
#6
Markus V Heppt, Lucie Heinzerling, Katharina C Kähler, Andrea Forschner, Michael C Kirchberger, Carmen Loquai, Markus Meissner, Friedegund Meier, Patrick Terheyden, Beatrice Schell, Rudolf Herbst, Daniela Göppner, Felix Kiecker, David Rafei-Shamsabadi, Sebastian Haferkamp, Margit A Huber, Jochen Utikal, Mirjana Ziemer, Irmgard Bumeder, Christiane Pfeiffer, Susanne G Schäd, Christoph Schmid-Tannwald, Julia K Tietze, Thomas K Eigentler, Carola Berking
BACKGROUND: Uveal melanoma (UM) is an ocular malignancy with high potential for metastatic spread. In contrast to cutaneous melanoma, immunotherapy has not yet shown convincing efficacy in patients with UM. Combined immune checkpoint blockade with checkpoint programmed cell death-1 (PD-1) and checkpoint cytotoxic T-lymphocyte antigen-4 (CTLA-4) inhibition has not been systematically assessed for UM to date. PATIENTS AND METHODS: Patients with metastatic UM treated with either PD-1 inhibitor monotherapy or combined PD-1 inhibitor and ipilimumab (an anti-CTLA-4 monoclonal antibody) were included from 20 German skin cancer centres...
September 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28629380/retinal-and-vitreous-metastases-from-hepatocholangiocarcinoma
#7
Anna Praidou, Sarita Jacob, Luciane Irion, Ramesh Sivaraj, Carl Groenewald, Sarah E Coupland, Heinrich Heimann
BACKGROUND: To report a case of metastatic hepatocholangiocarcinoma to the vitreous and retina. CASE PRESENTATION: A 70-year-old male, who was recently diagnosed with hepatocholangiocarcinoma, was complaining of floaters in his right eye over the past 5 months and was referred to the Liverpool Ocular Oncology Centre. On presentation, his visual acuity in the right eye was 6/24. Fundus exam revealed a whitish, unilateral, full-thickness retinal lesion at the inferotemporal arcade of his right eye, with vitreous infiltration and subretinal fluid...
June 19, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28626823/a-survey-of-ophthalmologists-and-gynecologists-regarding-termination-of-pregnancy-and-choice-of-delivery-mode-in-the-presence-of-eye-diseases
#8
Seyed-Farzad Mohammadi, Mojgan Letafat-Nejad, Elham Ashrafi, Hanieh Delshad-Aghdam
PURPOSE: To evaluate and compare the attitudes of ophthalmologists and gynecologists in suggesting appropriate approach to pregnancy in different ocular conditions. METHODS: Specialty-specific questionnaires on delivery mode and abortion indications for ophthalmic patients (refractive, vascular, oncologic, retinal, glaucoma, postoperation, posttrauma, and infectious) were designed and distributed among physician staff of Farabi Eye Hospital and Yas Women Hospital in Tehran...
June 2017: Journal of Current Ophthalmology
https://www.readbyqxmd.com/read/28572063/pattern-of-local-recurrence-after-i-125-episcleral-brachytherapy-for-uveal-melanoma-in-a-spanish-referral-ocular-oncology-unit
#9
Sara Sánchez-Tabernero, Ciro García-Alvarez, Ma Fe Muñoz-Moreno, Patricia Diezhandino, Pilar Alonso-Martínez, Jesus M de Frutos-Baraja, Francisco López-Lara, Maria A Saornil
PURPOSE: To describe the time, frequency, and clinical characteristics of treatment failure after I-125 brachytherapy in patients with uveal melanoma treated and followed in a Spanish referral ocular oncology unit. DESIGN: Prospective, consecutive, interventional case series. METHODS: Patients diagnosed with uveal melanoma from 1995 to 2016 and treated with episcleral brachytherapy were included. Demographic data collection, ophthalmic evaluation, ultrasound scan, and systemic studies were performed at baseline, every 6 months thereafter for 5 years, and subsequently at annual intervals...
August 2017: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/28559718/clinical-presentation-of-retinoblastoma-in-alexandria-a-step-toward-earlier-diagnosis
#10
Sameh E Soliman, Wesam Eldomiaty, Mohamed B Goweida, Amgad Dowidar
OBJECTIVE: To evaluate the clinical presentation of retinoblastoma in Alexandria, Egypt, correlate the timing of accurate diagnosis with the presence of advanced disease and identify causes of delayed presentation. METHODS: Retrospective noncomparative single institution study reviews demographic and clinical data of all new children with retinoblastoma presenting to Alexandria Main University ocular oncology clinic (OOC) from January 2012 to June 2014. Diagnosis time was from initial parental complaint to retinoblastoma diagnosis and referral time was from retinoblastoma diagnosis to presentation to the Alexandria OCC...
April 2017: Saudi Journal of Ophthalmology: Official Journal of the Saudi Ophthalmological Society
https://www.readbyqxmd.com/read/28549517/association-between-tumor-regression-rate-and-gene-expression-profile-after-iodine-125-plaque-radiotherapy-for-uveal-melanoma
#11
Prithvi Mruthyunjaya, Michael I Seider, Sandra Stinnett, Amy Schefler
PURPOSE: Gene expression profile (GEP) testing segregates uveal melanoma (UM) into 2 main prognostic classes. It is unknown if a greater tumor regression response after iodine 125 (I(125)) brachytherapy correlates with class 2 GEP status. The purpose of this study was to determine whether there is a significant relationship between the rate of UM height regression and GEP classification testing after I(125) plaque brachytherapy. DESIGN: Multicenter, retrospective cohort study...
May 23, 2017: Ophthalmology
https://www.readbyqxmd.com/read/28549348/ocular-toxicities-associated-with-targeted-anticancer-agents-an-analysis-of-clinical-data-with-management-suggestions
#12
Chen Fu, Dan S Gombos, Jared Lee, Goldy C George, Kenneth Hess, Andrew Whyte, David S Hong
Ocular toxicities are among the most common adverse events resulting from targeted anticancer agents and are becoming increasingly relevant in the management of patients on these agents. The purpose of this study is to provide a framework for management of these challenging toxicities based on objective data from FDA labels and from analysis of the literature. All oncologic drugs approved by the FDA up to March 14, 2015, were screened for inclusion. A total of 16 drugs (12 small-molecule drugs and 4 monoclonal antibodies) were analyzed for ocular toxicity profiles based on evidence of ocular toxicity...
May 5, 2017: Oncotarget
https://www.readbyqxmd.com/read/28464962/wernicke-encephalopathy-without-delirium-in-patients-with-cancer
#13
Hideki Onishi, Mayumi Ishida, Iori Tanahashi, Takao Takahashi, Yoshitada Taji, Kenji Ikebuchi, Daisuke Furuya, Tatsuo Akechi
OBJECTIVE: Wernicke encephalopathy (WE) is a neuropsychiatric disorder caused by thiamine deficiency. Several reports of WE in cancer patients are known. WE is sometimes overlooked because most patients do not exhibit its typical symptoms (e.g., delirium, ataxia, ocular palsy). If delirium is not present, a diagnosis of WE is difficult because delirium is the hallmark symptom of WE. METHOD: Taken from a series on WE in cancer, we report two patients who developed WE without delirium during periodic psycho-oncology outpatient visits...
May 3, 2017: Palliative & Supportive Care
https://www.readbyqxmd.com/read/28457288/the-use-of-semistructured-interviews-to-assess-quality-of-life-impacts-for-patients-with-uveal-melanoma
#14
Brianna C Kopp, R Trafford Crump, Ezekiel Weis
OBJECTIVE: There are limited studies on uveal melanoma and patient quality of life. However, the burden of implementing a patient-reported outcome measure to collect this information in a clinical setting is unknown. The objectives of this study were (i) to understand the issues of quality of life that are most important to patients undergoing treatment for uveal melanoma, (ii) to explore patient views on the European Organization for Research and Treatment of Cancer's (EORTC) ophthalmic oncology quality of life questionnaire (QLQ-OPT30), and (iii) to assess patient willingness to complete questionnaires measuring quality of life on an ongoing basis...
April 2017: Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie
https://www.readbyqxmd.com/read/28399344/the-development-of-ocular-oncology-watching-a-dream-come-true
#15
EDITORIAL
Jerry A Shields, Carol L Shields
No abstract text is available yet for this article.
March 2017: Asia-Pacific Journal of Ophthalmology
https://www.readbyqxmd.com/read/28395880/treatment-of-metastatic-uveal-melanoma-with-adoptive-transfer-of-tumour-infiltrating-lymphocytes-a-single-centre-two-stage-single-arm-phase-2-study
#16
Smita S Chandran, Robert P T Somerville, James C Yang, Richard M Sherry, Christopher A Klebanoff, Stephanie L Goff, John R Wunderlich, David N Danforth, Daniel Zlott, Biman C Paria, Arvind C Sabesan, Abhishek K Srivastava, Liqiang Xi, Trinh H Pham, Mark Raffeld, Donald E White, Mary Ann Toomey, Steven A Rosenberg, Udai S Kammula
BACKGROUND: Uveal melanoma is a rare tumour with no established treatments once metastases develop. Although a variety of immune-based therapies have shown efficacy in metastatic cutaneous melanoma, their use in ocular variants has been disappointing. Recently, adoptive T-cell therapy has shown salvage responses in multiple refractory solid tumours. Thus, we sought to determine if adoptive transfer of autologous tumour-infiltrating lymphocytes (TILs) could mediate regression of metastatic uveal melanoma...
June 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28353472/orbital-schwannoma-radiographic-and-histopathologic-correlation-in-15-cases
#17
Renelle Pointdujour-Lim, Sara E Lally, Jerry A Shields, Ralph C Eagle, Carol L Shields
PURPOSE: To evaluate the relationship between radiographic and histopathologic features of orbital schwannoma. METHODS: Retrospective review of 15 patients with orbital schwannoma managed at an ocular oncology service. RESULTS: The mean patient age at the time of presentation was 42 years old (median 40, range 15-64 years). The orbital schwannoma was found incidentally (n = 2) or with symptoms of proptosis (n = 2), blurred vision (n = 3), pain (n = 3), eyelid swelling (n = 2), diplopia (n = 2), or headache (n = 1)...
March 28, 2017: Ophthalmic Plastic and Reconstructive Surgery
https://www.readbyqxmd.com/read/28335891/the-majority-of-patients-with-metastatic-melanoma-are-not-represented-in-pivotal-phase-iii-immunotherapy-trials
#18
Marco Donia, Marie Louise Kimper-Karl, Katrine Lundby Høyer, Lars Bastholt, Henrik Schmidt, Inge Marie Svane
BACKGROUND: Recent randomised phase III trials have led to the approval of several immune checkpoint inhibitors for unresectable or metastatic melanoma (MM). These trials all employed strict patient selection criteria, and it is currently unknown how large proportion of 'real-world' patients diagnosed with MM is not represented in these trials. PATIENTS AND METHODS: The Danish MM Database contains data on the entire, unselected population of MM within a nationwide geographical area...
March 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28240745/the-biological-and-prognostic-significance-of-angiotropism-in-uveal-melanoma
#19
Raymond L Barnhill, Mengliang Ye, Aude Batistella, Marc-Henri Stern, Sergio Roman-Roman, Rémi Dendale, Olivier Lantz, Sophie Piperno-Neumann, Laurence Desjardins, Nathalie Cassoux, Claire Lugassy
Angiotropism is a marker of extravascular migration of melanoma cells along vascular and other structures and a prognostic factor in cutaneous melanoma. Because of this biological and prognostic importance in cutaneous melanoma, angiotropism was studied in uveal melanoma (UM). This retrospective study performed at a single ocular oncology referral center included 89 patients from the study period 2006-2008. All patients were diagnosed with UM from the choroid and/or ciliary body. All patients underwent enucleation for prognostic purposes and definitive therapy...
February 27, 2017: Laboratory Investigation; a Journal of Technical Methods and Pathology
https://www.readbyqxmd.com/read/28141766/choroidal-nevus-a-review-of-prevalence-features-genetics-risks-and-outcomes
#20
REVIEW
Jason L Chien, Kareem Sioufi, Thamolwan Surakiatchanukul, Jerry A Shields, Carol L Shields
PURPOSE OF REVIEW: To review the prevalence, clinical features, imaging findings, cytogenetics, and risks and outcomes of choroidal nevus. RECENT FINDINGS: Choroidal nevus is a benign melanocytic tumor, often discovered incidentally on ophthalmic examination. This lesion is generally well circumscribed and pigmented. The prevalence of choroidal nevus in postequatorial region in United States adults (≥40 years old) is approximately 5%. Choroidal nevus is associated with higher lifetime unopposed estrogen and greater BMI...
May 2017: Current Opinion in Ophthalmology
keyword
keyword
34324
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"